Company
Products and
Pipeline
We are a biotechnology company that is setting the new standard in healthcare, focused on innovative aesthetic and therapeutic offerings, as well as financial technology services for aesthetic practices.
DaxibotulinumtoxinA for Injection was approved for the treatment of moderate to severe frown lines (glabellar lines) in adults. Revance is also evaluating DaxibotulinumtoxinA for Injection for additional use in aesthetic medicine including the full upper face, forehead lines and crow’s feet and in therapeutic indications, including cervical dystonia and upper limb spasticity.
Revance Aesthetics is building the prestige market for aesthetics comprised of expertly created products and services that are available exclusively in select practices that produce exceptional consumer experiences and outcomes.
DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the first and only peptide formulated neuromodulator with long-lasting results, is FDA approved for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults.
The RHA® Collection, which stands for Resilient Hyaluronic Acid, is the only hyaluronic acid (HA) filler approved by the FDA for dynamic facial lines, wrinkles and folds that are moderate to severe, such as nasolabial folds (RHA® 2, RHA® 3, RHA® 4), and perioral rhytids (RHA Redensity™).1-10
The first-of-its-kind Relational Commerce platform helping to transform the practice-client relationship with seamless, simple, and smart loyalty and payment solutions exclusively for aesthetic practices.
Revance’s therapeutic pipeline seeks to bring innovation to multiple indications in muscle movement and pain disorders.
DAXXIFY® is now FDA approved for the treatment of cervical dystonia in adults.
REFERENCES
1 – RHA® DIRECTIONS FOR USE. NEWARK, CA: REVANCE THERAPEUTICS, INC, 2020.
2 – RHA® REDENSITY™ DIRECTIONS FOR USE. NEWARK, CA: REVANCE THERAPEUTICS, INC, 2021.
3 – JUVÉDERM VOLLURE XC INSTRUCTIONS FOR USE, MARCH 2017.
4 – RESTYLANE INSTRUCTIONS FOR USE, APRIL 2016.
5 – RESTYLANE REFYNE INSTRUCTIONS FOR USE, DECEMBER 2016.
6 – RESTYLANE DEFYNE INSTRUCTIONS FOR USE, DECEMBER 2016.
7 – JUVÉDERM VOLUMA INSTRUCTIONS FOR USE, SEPTEMBER 2016.
8 – RESTYLANE LYFT WITH LIDOCAINE INSTRUCTIONS FOR USE, NOVEMBER 2018.
9 – MONHEIT G ET AL. DERMATOL SURG. PUBLISHED ONLINE MARCH 24, 2020. DOI:10.1097/DSS.0000000000002391
10 – KAUFMAN-JANETTE J ET AL. J COSMET DERMATOL. PUBLISHED ONLINE AUGUST 24, 2019. DOI:10.1111/JOCD.13100.
DAXXIFY® (daxibotulinumtoxinA-lanm) injection IMPORTANT SAFETY INFORMATION
Indications
(daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients and for the treatment of cervical dystonia in adults.
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.
IMPORTANT SAFETY INFORMATION
Contraindications
DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).
Warnings and Precautions
Please refer to Boxed Warning for Distant Spread of Toxin Effect.
The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.
Adverse Reactions
The most commonly observed adverse reactions are:
Glabeller lines (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).
Cervical Dystonia (≥5%): headache (9%), injection site pain (8%), injection site erythema (5%), muscular weakness (5%), and upper respiratory tract infection (5%).
Drug Interactions
Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.
Use in Specific Populations
DAXXIFY® is not recommended for use in children or pregnant women.
Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.
To report side effects associated with DAXXIFY®, please visit safety.revance.com, or call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch
DAXI-004726
